Literature DB >> 518130

Comparison between tamoxifen and clomiphene therapy in women with anovulation.

I Gerhard, B Runnebaum.   

Abstract

Forty-eight women with various types of menstrual disorder were treated with tamoxifen: 30 of them ovulated as judged by serum progesterone concentrations and the basal body temperature (BBT) record. Serial determinations of serum FSH, LH, prolactin, and estradiol-17 beta showed that tamoxifen acts primarily on the hypothalamic-pituitary axis. Before or after the tamoxifen treatment cycles, 30 women received clomiphene. The ovulation rate in women with primary and secondary amenorrhea was similar, while women with oligomenorrhea tended to be more responsive to tamoxifen than to clomiphene. There was no difference between the drugs in the duration of the luteal phases nor in the pregnancy rate. The side effects during treatment with clomiphene were pronounced than during tamoxifen therapy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 518130     DOI: 10.1007/bf02109916

Source DB:  PubMed          Journal:  Arch Gynecol        ISSN: 0170-9925


  44 in total

1.  EFFECTS OF CLOMIPHENE CITRATE ON ANOVULATORY OVARIAN FUNCTION.

Authors:  G M RILEY; T N EVANS
Journal:  Am J Obstet Gynecol       Date:  1964-05-01       Impact factor: 8.661

2.  The measurement of plasma progesterone.

Authors:  T Yoshimi; M B Lipsett
Journal:  Steroids       Date:  1968-04       Impact factor: 2.668

3.  Effect of clomiphene citrate in polycystic ovary syndrome: Relationship between serum gonadotropin and corpus luteum function.

Authors:  S S Yen; P Vela; K J Ryan
Journal:  J Clin Endocrinol Metab       Date:  1970-07       Impact factor: 5.958

4.  [Further clinical experiences in the treatment of monophasic cycle anomalies with clomiphene (Dyneric)].

Authors:  J Zander; F Leidenberger; K Holzmann; B Runnebaum; G Buntru; I Winkhaus; D Heinrichs
Journal:  Geburtshilfe Frauenheilkd       Date:  1970-06       Impact factor: 2.915

5.  Regulation of the human menstrual cycle.

Authors:  L Speroff; R L Vande Wiele
Journal:  Am J Obstet Gynecol       Date:  1971-01-15       Impact factor: 8.661

Review 6.  Management of infertility resulting from anovulation.

Authors:  R Jewelewicz
Journal:  Am J Obstet Gynecol       Date:  1975-08-15       Impact factor: 8.661

7.  Relationship between the plasma levels of luteinizing hormone and progesterone during the normal menstrual cycle.

Authors:  J D Neill; E D Johansson; J K Datta; E Knobil
Journal:  J Clin Endocrinol Metab       Date:  1967-08       Impact factor: 5.958

8.  New synthetic agent for the induction of ovulation: preliminary trials in women.

Authors:  A Klopper; M Hall
Journal:  Br Med J       Date:  1971-01-16

9.  Serum levels of unconjugated aetiocholanolone androstenedione, testosterone, dehydroepiandrosterone, aldosterone, progesterone and oestrogens during the normal menstrual cycle.

Authors:  M Frölich; E C Brand; E V van Hall
Journal:  Acta Endocrinol (Copenh)       Date:  1976-03

10.  Radioimmunosorbent assay of follicle-stimulating hormone and luteinizing hormone in serum and urine from men and women.

Authors:  L Wide; S J Nillius; C Gemzell; P Roos
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1973
View more
  5 in total

1.  Effects of estradiol and some antiestrogens (clomiphene, tamoxifen, and hydroxytamoxifen) on luteinizing hormone secretion by rat pituitary cells in culture.

Authors:  G Emons; O Ortmann; S Thiessen; R Knuppen
Journal:  Arch Gynecol       Date:  1986

2.  The Royal Marsden Hospital pilot tamoxifen chemoprevention trial.

Authors:  T J Powles; A L Jones; S E Ashley; M E O'Brien; V A Tidy; J Treleavan; D Cosgrove; A G Nash; N Sacks; M Baum
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 3.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

4.  Ovarian cysts in women receiving tamoxifen for breast cancer.

Authors:  M J Mourits; E G de Vries; P H Willemse; K A ten Hoor; H Hollema; W J Sluiter; H W de Bruijn; A G van der Zee
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

5.  Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case-control study.

Authors:  A J Swerdlow; M E Jones
Journal:  Br J Cancer       Date:  2007-02-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.